Table 1.

Model input parameters.

Model input	Value	PSA distribution	Sources
Patient characteristics
Starting age, years	55		Lee et al. (9)
Proportion of curable recurrence, %			Lee et al. a (10)
Treatment	56.6
Control	47.8
Incidence rate of curative treatments (/person-year), mean (95% CI)			Lee et al. a (10)
Resection	0.0888 (0.0385, 0.1390)	Normal
Radiofrequency ablation	0.3033 (0.2105, 0.3962)	Normal
Percutaneous ethanol injection	0.2071 (0.1304, 0.2839)	Normal
Liver transplantation	0.0148 (0.0000, 0.0353)	Normal
Utilities
Health state utility (95% CI)			Pollom et al. (16)
Recurrence-free state	0.88 (0.85, 0.92)	Beta
Curable recurrence	0.88 (0.85, 0.92)	Beta
Incurable recurrence	0.40 (0.32, 0.48)	Beta
Treatment-related disutility			Ock et al. b (17)
Resection	- 0.26
Radiofrequency ablation	- 0.33
Percutaneous ethanol injection	- 0.33
Transplantation	- 0.21
Costs (USD), mean (SD) c
Treatment cost (per injection)	3,807
Health state cost (per cycle)
Recurrence-free state d	211 (21)	Gamma	Micro-costing
Curable recurrence d	211 (21)	Gamma	Micro-costing
Incurable recurrence	2,505 (711)	Gamma	HIRA data
Event cost for curative treatments			HIRA data
Resection	8,082 (3,015)	Gamma
Radiofrequency ablation	2,085 (1,039)	Gamma
Percutaneous ethanol injection	1,640 (1,282)	Gamma
Liver transplantation	67,142 (23,888)	Gamma
End-of-life cost d	6,798 (679)	Gamma	Yang, (18)

CI, confidence interval; HIRA, Health Insurance Review & Assessment Service of Korea; PSA, probabilistic sensitivity analysis; SD, standard deviation.

^aDerived from post-hoc analysis of recurrence data from phase III trial (Lee et al., 2015 & Lee et al., 2018).

^bConverted to disutility from Ock et al., 2017.

^c1 USD = 1,166.51 KRW.

^dStandard deviation is assumed to be 10% of the mean value.